Literature DB >> 30614523

Long non-coding RNAs differential expression in breast cancer subtypes: What do we know?

Carolina Mathias1, Erika P Zambalde1, Philip Rask2, Daniela F Gradia1, Jaqueline C de Oliveira1.   

Abstract

Breast Cancer (BC) is the most commonly diagnosed cancer and is the leading cause of cancer deaths in women. BC is a heterogeneous disease with different clinical and genetic features. According to immunohistochemical markers, BC is subdivided into four main subtypes: luminal A, luminal B, ERBB2 positive and triple negative. Long non-coding RNAs (lncRNAs) are transcripts with more than 200 nucleotides and deregulated lncRNAs are associated with human diseases, including BC. In order to improve BC molecular classification, non-coding RNAs (ncRNAs), including lncRNAs, have been used. In this review, we focus on lncRNAs with differential expression in BC subtypes and how these RNAs may act to contribute to BC heterogeneity. We also emphasize the potential of these lncRNAs as biomarkers.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  ER positive; breast cancer; breast cancer subtypes; lncRNA

Mesh:

Substances:

Year:  2019        PMID: 30614523     DOI: 10.1111/cge.13502

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  20 in total

1.  Response to Yang et. al.

Authors:  Yoshimi Asano; Chiemi Saigo; Yusuke Kito; Yoshinori Iwata; Kazuhiro Yoshida; Tamotsu Takeuchi
Journal:  J Mol Med (Berl)       Date:  2019-03-23       Impact factor: 4.599

Review 2.  Long noncoding RNAs and exosomal lncRNAs: classification, and mechanisms in breast cancer metastasis and drug resistance.

Authors:  Hassan Yousefi; Maryam Maheronnaghsh; Fatemeh Molaei; Ladan Mashouri; Amir Reza Aref; Majid Momeny; Suresh K Alahari
Journal:  Oncogene       Date:  2019-10-10       Impact factor: 9.867

Review 3.  Circulating non-coding RNAs as a diagnostic and management biomarker for breast cancer: current insights.

Authors:  Hamed Hosseinalizadeh; Mehrdad Mahmoodpour; Ammar Ebrahimi
Journal:  Mol Biol Rep       Date:  2021-10-22       Impact factor: 2.316

4.  lincRNA-RP11400K9.4 Regulates Cell Survival and Migration of Breast Cancer Cells.

Authors:  Miguel A FernÁndez-Rojas; Jorge Melendez-Zajgla; Vilma Maldonado Lagunas
Journal:  Cancer Genomics Proteomics       Date:  2020 Nov-Dec       Impact factor: 4.069

5.  LINC00355 regulates p27KIP expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer.

Authors:  Jessica M Silva-Fisher; Christopher A Maher; Abdallah M Eteleeb; Prasanth K Thunuguntla; Kyla Z Gelev; Cynthia Y Tang; Emily B Rozycki; Alexander Miller; Jonathan T Lei; Reyka G Jayasinghe; Ha X Dang; Nicole M White; Jorge S Reis-Filho; Elaine R Mardis; Matthew J Ellis; Li Ding
Journal:  NPJ Breast Cancer       Date:  2022-04-13

6.  SNPs in lncRNA Regions and Breast Cancer Risk.

Authors:  Maija Suvanto; Jonathan Beesley; Carl Blomqvist; Georgia Chenevix-Trench; Sofia Khan; Heli Nevanlinna
Journal:  Front Genet       Date:  2020-06-30       Impact factor: 4.599

7.  LOXL1-AS1 predicts poor prognosis and promotes cell proliferation, migration, and invasion in osteosarcoma.

Authors:  Si Chen; Weiguo Li; Ai Guo
Journal:  Biosci Rep       Date:  2019-04-30       Impact factor: 3.840

8.  MIR100HG: a credible prognostic biomarker and an oncogenic lncRNA in gastric cancer.

Authors:  Jun Li; Qingfeng Xu; Wen Wang; Shaojun Sun
Journal:  Biosci Rep       Date:  2019-04-05       Impact factor: 3.840

Review 9.  Long Non-Coding RNA: Dual Effects on Breast Cancer Metastasis and Clinical Applications.

Authors:  Qi-Yuan Huang; Guo-Feng Liu; Xian-Ling Qian; Li-Bo Tang; Qing-Yun Huang; Li-Xia Xiong
Journal:  Cancers (Basel)       Date:  2019-11-16       Impact factor: 6.639

Review 10.  Long noncoding RNAs in osteosarcoma via various signaling pathways.

Authors:  Jinming Han; Xiaohan Shen
Journal:  J Clin Lab Anal       Date:  2020-04-06       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.